Anticoagulation management during cross-clamping and bypass

Area of Science:

• Cardiovascular Surgery
• Hematology
• Anesthesiology

Background:

• Anticoagulation is essential for cardiopulmonary bypass (CPB) and surgeries involving aortic occlusion.
• Coagulation and fibrinolysis are activated during CPB, necessitating careful management.
• Thrombosis and excessive bleeding are risks associated with inadequate anticoagulation.

Purpose of the Study:

• To review the current strategies for anticoagulation management during CPB and aortic cross-clamp procedures.
• To highlight the importance of appropriate anticoagulation dosing, monitoring, and maintenance.
• To discuss the role of unfractionated heparin and its monitoring methods.

Main Methods:

• Review of existing literature on anticoagulation during CPB and aortic occlusion.
• Analysis of current monitoring techniques, including activated clotting time (ACT) and heparin concentration.
• Discussion of unfractionated heparin as the primary anticoagulant in these settings.

Main Results:

• Unfractionated heparin is the predominant anticoagulant used in CPB and aortic occlusion surgeries.
• Activated clotting time (ACT) and heparin concentration are key monitoring parameters.
• Effective anticoagulation prevents circuit thrombosis and minimizes hemostatic system activation.

Conclusions:

• Optimal anticoagulation is vital for the success of CPB and aortic occlusion surgeries.
• Current management relies heavily on unfractionated heparin and ACT monitoring.
• Further research into novel anticoagulants and advanced monitoring may improve patient outcomes.